Business Wire

MA-EXAGRID

15.11.2022 14:01:46 CET | Business Wire | Press release

Share
ExaGrid Launches Version 6.2 with 5 Key Performance, Integration, and Security Features

ExaGrid®, the industry's only Tiered Backup Storage solution, today announced the release of software Version 6.2, which begins shipping in early December 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005053/en/

ExaGrid is constantly driving improvements in five key areas: ingest performance for the fastest backups and shortest backup window, fastest restores to keep user productive, scalability to ensure a fixed-length backup window as data grows as well as no forklift upgrades and no planned product obsolescence, lowest cost up front and over time, and a strong security story including the ability to recover after a security attack such as ransomware.

ExaGrid's Unique Architecture employs:

  • Front-end disk-cache Landing Zone for fast backups
    • Optimized for large backup jobs, parallel backup support (job concurrency), no inline deduplication to slow backups down, encryption at the drive level to increase performance, and integrations with key backup applications for front-end load balancing.
    • Fast restores as the data is in the native backup application format and is non-deduplicated to avoid compute-intensive data rehydration
  • Scale-out architecture
    • Keeps a fixed-length backup window as data grows
    • Eliminates disruptive and costly forklift upgrades
    • Can mix and match any age and any size appliance eliminating planned product obsolescence to reduce costs over time
  • Non-network-facing Repository Tier
    • Deduplicated data to efficiently store all current and long-term retention data for cost savings
    • Not visible or accessible from the network
    • Delayed deletes to ensure data deleted on the front-end Landing Zone is not immediately deleted in the repository ensuring data is ready for recovery after an attack
    • Immutable data objects that are not deleted, changed, or modified to ensure recovery from encryption events

5 Key Updates in Version 6.2

Veritas NetBackup Single Target Storage Pool
ExaGrid has integrated with NetBackup and presents a single virtualized target pool of storage at each site. This approach automates job management between Veritas NetBackup and ExaGrid, where backup data is automatically sent to available ExaGrid appliances for front-end performance. Backup data is directed into any ExaGrid appliance as all ExaGrid appliances are in a single integrated scale-out system. ExaGrid automatically load balances all data across all non-network facing repositories for full storage utilization and globally deduplicates data across all repositories for maximum storage savings.

Veritas IT Analytics
ExaGrid has integrated with Veritas IT analytics, allowing reporting on key data statistics from the ExaGrid storage. This allows enterprises to include ExaGrid Tiered Backup storage along with unified insights for backup, storage, and virtual infrastructure.

ExaGrid, including Single Target Storage Pool and support of NetBackup Analytics, now has a total of 9 Veritas NetBackup integrations, including support of NetBackup Accelerator, OST Integration, integration with NetBackup media server hardware, AIR (Auto Image Replication), and GRT (granular level restore), optimized deduplication, and instant recovery.

New ExaGrid Cloud Tier Features and Integrations
ExaGrid physical appliances on premise in the data center can replicate data to the public clouds for disaster recovery (DR). ExaGrid has improved the performance and scalability of its ExaGrid Cloud Tier for Amazon AWS and has added ExaGrid Cloud Tier support for Microsoft Azure. ExaGrid physical on-site appliances replicate the deduplicated data in the repository to AWS or Azure, which is then written to AWS or Azure storage for long-term retention. The deduplicated data uses about 1/50th of the bandwidth versus undeduplicated data. ExaGrid encrypts the data in transit, and the cloud providers encrypt the data at rest.

Improved Performance
ExaGrid has improved its Adaptive Deduplication performance, increasing the Repository Tier's overall performance and further increasing the scalability and recovery points of data in the non-network-facing Repository Tier and offsite disaster recovery copy.

ExaGrid has greatly improved the performance of Veeam synthetic fulls (Veeam V12) by adding support for Veeam's Fast Clone technology in ExaGrid repositories. The synthetics fulls are at least 30X faster than previous versions.

Improved Security
ExaGrid has a strong ransomware recovery solution with a non-network-facing Repository Tier (tiered air gap), delayed delete policy, immutable data objects, and 2FA support. ExaGrid has added two new features:

  • An alert on large delete is generated as an early detection warning if a threat actor/hacker is trying to delete a large amount of recently ingested data (above a set operational threshold) on the ExaGrid front-end Landing Zone.
  • An alert on data deduplication change is generated when the deduplication ratio changes below a set threshold signaling that a large amount of encrypted data is being sent to the ExaGrid front-end Landing Zone or that the data on the Landing Zone is being encrypted.

These features add an early alert warning in addition to the current ExaGrid Retention Time-Lock (RTL) functionality, ensuring that the data in the non-network-facing tier is available for recovery.

"ExaGrid continues to focus on improving backup and restore performance, scalability, cost savings, and security," said Bill Andrews, CEO of ExaGrid. "Since ExaGrid is 100% focused on backup storage, all we do is obsess about making backup storage better. We are the only company worldwide focusing solely on backup storage. It is a testament to the product that we are installed in over 80 countries worldwide, have 99% of our customers on yearly maintenance and support contracts, have a NPS of +81, and a customer retention rate of 95%. All of these numbers are market-leading in storage. ExaGrid is a financially healthy and growing company that is cash positive, P&L positive, and EBITDA positive. The combination of our product, customer support, and financial strength is why customers trust ExaGrid Tiered Backup Storage."

About ExaGrid
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid's Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid's scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks.

ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, Iberia, India, Israel, Japan, Mexico, Nordics, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.

Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup in our customer success stories. Check out our 100+ Gartner Peer Insight Reviews. ExaGrid is proud of our +81 NPS score.

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005053/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye